Current cervical cancer screening methods, such as Pap smears have limitations, resulting in poor attendance in screening programs. Women would prefer easy, and non-invasive techniques that are not clinician dependent.
Urine as a sample type is well-accepted. Additionally, as Human Papillomavirus (HPV), the most common cause of cervical cancer can be detected in urine, this sample has the potential to reach a wider population, especially women who do not participate in screening.
Novosanis’ Colli-Pee® device allows for standardized, volumetric collection of first-void urine. The device architecture also enables immediate mixing of the sample with a urine preservative, improving the stability of the sample.
- Why use first-void urine
- Limitations with current cervical cancer screening methods
- Potential of self-sampling methods, including urine sampling
- Colli-Pee® as a urine collection device